Resolutionrx Ltd News Today

RespireRx Pharmaceuticals (OTC:RSPI) has announced an agreement with Ponto Ventures LLC under which Will Clodfelter will serve as its senior vice president...

ResolutionRx Ltd entered into an agreement with Ab Initio Pharma to manufacture and test a dronabinol lipid nanoparticle formulation for OSA.

Active stocks, known for their frequent price shifts and sustained market interest, are a magnet for savvy investors seeking profits. Lets take a closer look at some of the top OTC stocks from this...

Market temperatures are slowly rising with the summer heat. With some stocks posting double-digit gains, overvaluation concerns are becoming rife. Nevertheless, the focus is increasingly on... -Today at 03:28 am- MarketScreener

RespireRx is moving its cannabinoid program to its subsidiary, ResolutionRx, to develop a dronabinol-based treatment for OSA.

RespireRx Pharmaceuticals Inc. (OTCPK:RSPI), focused on the discovery and development of treatments to combat diseases caused by disruption of neuronal signaling, and ResolutionRx Ltd, an unlisted public Australian company, and a subsidiary of RespireRx on August 3, 2023, entered into a series of bilateral agreements intended to transfer the Re

ResolutionRx Director Arnold Lippa joins Natalie Stoberman from the Proactive studio to discuss its recent letter of intent for financing with Radium...

RespireRx Pharmaceuticals (OTC:RSPI) Inc announced that its recently created Australia-based subsidiary ResolutionRx Ltd has signed a letter of intent (LOI)...

RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform - read this article along with other careers information, tips and advice on BioSpace